5月4日 - ** 生物技术公司Mirum Pharmaceuticals MIRM.O的股价上涨11.9%，至108.09美元
** 该公司表示，其实验性药物volixibat在一项中期研究中达到了主要目标 (link)，成功缓解了原发性硬化性胆管炎（一种罕见肝病）患者的严重瘙痒
** 称该药物将瘙痒评分较基线降低了2.72分，而安慰剂组仅降低1.08分，经安慰剂校正后的获益为1.64分
** 加拿大皇家银行资本市场表示：“我们预计股价将小幅上涨，因为鉴于目前尚无获批药物，原预期门槛较低，因此该药在原发性硬化性胆管炎（PSC）领域的成功或许在预期之中”
** 计入当日涨幅，MIRM今年以来累计上涨36.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.